Somatostatin Receptor Clinical Trials

6 recruitingLast updated: May 29, 2026

There are 6 actively recruiting somatostatin receptor clinical trials across 12 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Barcelona, Spain, Bethesda, Maryland, United States, Madrid, Spain. Updated daily from ClinicalTrials.gov.


Somatostatin Receptor Trials at a Glance

6 actively recruiting trials for somatostatin receptor are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Barcelona, Bethesda, and Madrid. Lead sponsors running somatostatin receptor studies include National Cancer Institute (NCI), ITM Solucin GmbH, and Novartis Pharmaceuticals.

Browse somatostatin receptor trials by phase

Treatments under study

About Somatostatin Receptor Clinical Trials

Looking for clinical trials for Somatostatin Receptor? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Somatostatin Receptor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Somatostatin Receptor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Neuroendocrine TumorsSomatostatin Receptor-positive Neuroendocrine Tumor
University of Wisconsin, Madison10 enrolled1 locationNCT06122610
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752
Recruiting
Phase 1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Solid TumorLymphomaGIST+5 more
ITM Solucin GmbH20 enrolled5 locationsNCT06441331
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 1

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Solid TumorNeuroendocrine TumorsGep Net+6 more
RayzeBio, Inc.104 enrolled4 locationsNCT07165132
Recruiting
Phase 1Phase 2

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798